Senores Pharmaceuticals IPO Details
IPO Date	December 20, 2024 to December 24, 2024
Listing Date	December 30, 2024
Face Value	₹10 per share
Issue Price Band	₹372 to ₹391 per share
Issue Price Final	₹391 per share
Lot Size	38 Shares
Sale Type	Fresh Capital-cum-Offer for Sale
Total Issue Size	1,48,87,723 shares
(aggregating up to ₹582.11 Cr)
Fresh Issue	1,27,87,723 shares
(aggregating up to ₹500.00 Cr)
Offer for Sale	21,00,000 shares of ₹10
(aggregating up to ₹82.11 Cr)
Issue Type	Bookbuilding IPO
Listing At	BSE, NSE
Share Holding Pre Issue	3,32,65,865 shares
Share Holding Post Issue	4,60,53,588 shares
Senores Pharmaceuticals IPO Reservation
Senores Pharmaceuticals IPO offers total 1,48,87,723 shares. Out of which 1,11,09,543 (74.62%) allocated to QIB, 44,43,818 (29.85%) allocated to QIB, 22,21,908 (14.92%) allocated to NII, 14,81,272 (9.95%) allocated to RII and 66,65,725 (44.77%) allocated to Anchor investors.

Investor Category	Shares Offered	Maximum Allottees
QIB Shares Offered	1,11,09,543 (74.62%)	NA
NII (HNI) Shares Offered	22,21,908 (14.92%)	NA
Retail Shares Offered	14,81,272 (9.95%)	38,980
Employee Shares Offered	75,000 (0.50%)	NA
Total Shares Offered	1,48,87,723 (100.00%)	
Investor Category Reservations
Application Category	Maximum Bidding Limits	Bidding at Cut-off Price Allowed
Only RII	Up to Rs 2 Lakhs	Yes
Only sNII	Rs 2 Lakhs to Rs 10 Lakhs	No
Only bNII	Rs 10 Lakhs to NII Reservation Portion	No
Only employee	Up to Rs 2 Lakhs	Yes
Employee + RII/NII	
Employee limit: Up to Rs 2 Lakhs (In certain cases, employees are given discount if bidding amount is upto Rs. 2 lakhs)
If applying as RII: Upto Rs. 2 lakhs
If applying as NII: sNII > Rs. 2 lakhs and upto Rs. 10 lakhs and bNII > Rs. 10 lakhs
Yes for Employee and RII/NII
Senores Pharmaceuticals IPO Anchor Investors Details
Senores Pharmaceuticals IPO raises ₹260.63 crore from anchor investors. Senores Pharmaceuticals IPO Anchor bid date is December 19, 2024. Senores Pharmaceuticals IPO Anchor Investors list

Bid Date	December 19, 2024
Shares Offered	66,65,725
Anchor Portion Size (In Cr.)	260.63
Anchor lock-in period end date for 50% shares (30 Days)	January 24, 2025
Anchor lock-in period end date for remaining shares (90 Days)	March 25, 2025
Senores Pharmaceuticals IPO Timeline (Tentative Schedule)
Senores Pharmaceuticals IPO opens on December 20, 2024, and closes on December 24, 2024.

IPO Open Date	Fri, Dec 20, 2024
IPO Close Date	Tue, Dec 24, 2024
Tentative Allotment	Thu, Dec 26, 2024
Initiation of Refunds	Fri, Dec 27, 2024
Credit of Shares to Demat	Fri, Dec 27, 2024
Tentative Listing Date	Mon, Dec 30, 2024
Cut-off time for UPI mandate confirmation	5 PM on Tue, Dec 24, 2024
Senores Pharmaceuticals IPO Lot Size
Investors can bid for a minimum of 38 shares and in multiples thereof.  The following table depicts the minimum and maximum investment by Individual Investors (Retail) and HNI in terms of shares and amount.

Application	Lots	Shares	Amount
Retail (Min)	1	38	₹14,858
Retail (Max)	13	494	₹1,93,154
S-HNI (Min)	14	532	₹2,08,012
S-HNI (Max)	67	2,546	₹9,95,486
B-HNI (Min)	68	2,584	₹10,10,344
Senores Pharmaceuticals IPO Promoter Holding
The promoters of the company are Swapnil Jatinbhai Shah and Ashokkumar Vijaysinh Barot.
Promoter Holding Pre Issue	71.10%
Promoter Holding Post Issue	45.77%
Note : The value will be calculated using Equity Dilution = Share Holding Pre Issue - Share Holding Post Issue

About Senores Pharmaceuticals Ltd.
Incorporated in December 2017, Senores Pharmaceuticals Limited develops and manufactures a range of pharmaceutical products primarily for the regulated markets of the US, Canada, and the UK, while also serving emerging markets.

The company's product portfolio consists of Amphetamine Sulfate Tablets, Hydroxychloroquine Sulfate Tablets, Ketoconazole Tablets, Butalbital, Acetaminophen and Caffeine Capsules, Mexiletine Hydrochloride Capsules, Ketorolac Tromethamine Tablets, Diclofenac Potassium Tablets, Diclofenac Potassium Tablets, Nicardipine Hydrochloride Capsules, Escitalopram Tablets, Prochlorperazine Maleate Tablets USP, Terazosin Capsules USP, Morphine Sulfate Tablets, Methadone Hydrochloride Tablets, Cyclobenzaprine Hydrochloride Tablets, Irbesartan Tablets, Risperidone Tablets Topiramate Capsules, and Ivermectin Tablets for regulated markets.

As of September 30, 2024, the company has launched 55 products in key therapeutic areas, including antibiotics and anti-fungal treatments. They have established partnerships with distributors and hospitals across several states in India.

As of September 30, 2024, the company operates three dedicated R&D facilities in India and the US.

The company operates in Emerging Markets across 43 countries and manufactures critical care injectables and APIs.

The company's manufacturing unit is situated in Ahmedabad, Gujrat.

Competitive Strength

The company serves the US, Canada, and the UK regulated markets with its US FDA-approved manufacturing facility.
A unique product portfolio tailored for regulated markets developed in a brief period.
Long-term marketing agreements with pharmaceutical companies in the US, Canada, and the United Kingdom regulated markets.
Presence in the Emerging Markets with a product portfolio, including speciality or complex products.
Robust R&D capabilities driving our differentiated portfolio of products.
Experieced Management Team
Company Financials
Senores Pharmaceuticals Limited Financial Information (Restated Consolidated)
Senores Pharmaceuticals Limited's revenue increased by 457% and profit after tax (PAT) rose by 288% between the financial year ending with March 31, 2024 and March 31, 2023.

Period Ended	30 Sep 2024	31 Mar 2024	31 Mar 2023	31 Mar 2022
Assets	678.08	621.88	131.05	59.15
Total Income	183.35	217.34	39.02	14.63
Profit After Tax	23.94	32.71	8.43	0.99
Net Worth	319.06	231.71	45.5	36.59
Reserves and Surplus	263.36	175.94	35.25	25.37
Total Borrowing	242.03	248.38	60.76	14.21
Amount in ₹ Crore
Key Performance Indicator (KPI)
The market capitalization of Senores Pharmaceuticals IPO is ₹1350.70 Cr.

KPI as of Sun, Mar 31, 2024.

KPI	Values
ROE	23.60%
ROCE	11.73%
Debt/Equity	1.07
RoNW	23.60%
PAT Margin	15.25%
Price to Book Value	5.84
Check Senores Pharmaceuticals IPO Peer Comparison here.
Pre IPO	Post IPO
EPS Rs	9.83	13.86
P/E (x)	39.77	28.21
Note:
The Pre IPO EPS is calculated based on Pre issue shareholding as on date of RHP and the latest FY earnings as of March 31, 2024 that is available in RHP.
The Post Issue EPS is calculated based on the Post issue shareholding and annualized FY earnings of September 30, 2024 that is available in RHP.
Objects of the Issue (Senores Pharmaceuticals IPO Objectives)
The Company proposes to utilise the Net Proceeds towards funding the following objects:

Investment in one of the Subsidiaries, Havix Group, Inc. d/b/aAavis Pharmaceuticals(“Havix”), to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in the Atlanta Facility;
Repayment/pre-payment, in full or in part, of certain borrowings availed by the Company;
Investment in the Subsidiary, namely, Havix, for re-payment/pre-payment in whole or part of certain borrowings availed by such Subsidiary;
Funding the working capital requirements of the Company;
Investment in the Subsidiaries, namely, Senores Pharmaceuticals Inc. (“SPI”)and Ratnatris Pharmaceutical Private Limited (“Ratnatris”), to fund their working capital requirements.
Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.
Senores Pharmaceuticals IPO Review
[Dilip Davda]  The company is focusing on pharma business for global markets through its global research and marketing skills. The company marked growth in its top and bottom lines for reported periods. It holds good long term relations with marquee clients. The sudden boost in its top and bottom lines from FY24 onwards raise eyebrows. Based on its recent financial performances, the issue appears aggressively priced. Well-informed investors may park funds for long term. Read detail review...

Senores Pharmaceuticals IPO Subscription Status (Bidding Detail)
The Senores Pharmaceuticals IPO is subscribed 97.86 times on December 24, 2024 6:19:11 PM (Day 3). The public issue subscribed 93.16 times in the retail category, 97.84 times in the QIB category, and 100.35 times in the NII category. Check Day by Day Subscription Details (Live Status)

Category	Subscription (times)	Shares Offered	Shares bid for
QIB	97.84	44,43,817	43,47,78,102
NII	100.35	22,21,909	22,29,63,632
    bNII (bids above ₹10L)	95.25	15,18,605	14,46,53,764
    sNII (bids below ₹10L)	111.35	7,03,304	7,83,09,868
Retail	93.16	14,81,272	13,79,96,126
Total	97.86	81,46,998	79,72,31,982
Total Application : 37,01,011

Senores Pharmaceuticals IPO Prospectus
  ›  Senores Pharmaceuticals IPO DRHP
  ›  Senores Pharmaceuticals IPO RHP
  ›  Anchor Investors in Senores Pharmaceuticals IPO
  ›  Senores Pharmaceuticals IPO Final Prospectus
Senores Pharmaceuticals IPO Listing Details
Listing Date	December 30, 2024
BSE Script Code	544319
NSE Symbol	SENORES
ISIN	INE0RB801010
Final Issue Price	₹391 per share
NSE Listing Group	EQ (Rolling)
BSE Listing Group	B (Rolling)
Pre-Open Session - NSEPre-Open Session - BSE

Listing Day Trading Information
Price Details	NSE SME
Final Issue Price	₹391.00
Open	₹593.70
Low	₹538.85
High	₹609.00
Last Trade	₹557.80